Clinical Trial Update: Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] [Phase 2]

View source ↗

Summary

Phase 2 trial update on MCO-010 optogenetic therapy for retinitis pigmentosa shows efficacy and safety data collected in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis
• Retinitis Pigmentosa

Drugs mentioned

• MCO-010 (MCO-010)

Snippet

Sponsor: Nanoscope Therapeutics Inc. | Conditions: Retinitis Pigmentosa, Retinitis | Phase 2 | Status: COMPLETED